U.S. Banks Stock News

SolarEdge Technologies (SEDG) grabbed attention after a 12.7% jump, as Jefferies and Bank of America upgraded the stock, citing a potential demand rebound, regained top U.S. inverter share and a stronger earnings outlook. See our latest analysis for SolarEdge Technologies. The sharp 13.29% 1 day share price return to US$51.73 sits on top of a 47.97% 30 day and 78.01% 90 day share price return. The 1 year total shareholder return of about 3x contrasts with a 5 year total shareholder return...

SEC approval puts Nasdaq’s tokenization plans in focus The SEC’s decision to let certain securities listed on Nasdaq (NDAQ) trade and settle in tokenized form on blockchain, combined with its Payward partnership, is drawing fresh attention to the stock’s role in digital assets. See our latest analysis for Nasdaq. Nasdaq’s recent tokenization announcements sit against a mixed share price backdrop, with a 6.06% 1 month share price return but a 10.68% decline year to date. At the same time, a 1...

Skyworks Solutions (NasdaqGS:SWKS) and Qorvo have agreed to merge, bringing together two long time rivals in radio frequency chip manufacturing. The companies plan to combine their product portfolios for mobile devices and connectivity solutions, subject to regulatory and shareholder approvals. The announcement reflects a move toward greater scale and broader customer coverage in key wireless and connectivity markets. For you as an investor, this merger brings two established radio...

What recent returns say about Constellation Brands today Constellation Brands (STZ) has seen a 1.5% decline over the past day and a small loss over the past week, while the share price shows a larger decline over the past year. At a recent close of US$149.62, the stock is down about 4% over the past month but up roughly 11% in the past 3 months. This gives investors mixed short-term and more recent longer-period performance signals. See our latest analysis for Constellation Brands. The recent...

Novo Nordisk (NYSE:NVO) has received two recent FDA warnings related to its GLP-1 franchise. The company is experiencing rising GLP-1 competition from Eli Lilly and newer entrants such as Pfizer. These developments are emerging as revenue growth slows and margins come under pressure. Novo Nordisk, best known for its diabetes and obesity treatments, now finds its GLP-1 leadership under closer regulatory and competitive scrutiny. While recent attention has focused on valuation and telehealth...

European cloud infrastructure providers have filed a competition complaint with the EU against Broadcom (NasdaqGS:AVGO) over recent VMware licensing changes. The complaint, brought by industry group CISPE, alleges abuse of market position through the termination of prior VMware partner programs and tougher new license terms. Complainants are asking the European Commission to impose interim measures to halt the alleged practices and restore access to earlier partner arrangements. For...

Viatris (VTRS) has drawn fresh attention after announcing an Investor Event where leaders plan to lay out the company’s vision through 2030, including growth drivers, pipeline plans, portfolio choices, and capital return priorities. See our latest analysis for Viatris. Viatris shares currently trade at US$13.20, with a 30-day share price return of 17.76% decline, a 90-day share price return of 10.65%, and a 1-year total shareholder return of 50.99%. If the Investor Event has you thinking...

Tutor Perini (TPC) has drawn investor attention after recent share price swings, including a 4.1% decline over the past day and a 14.5% drop over the past month, despite solid reported profitability and revenue. See our latest analysis for Tutor Perini. The recent 1 day share price return of 4.1% decline and 30 day share price return of 14.5% decline sit in sharp contrast to a very large 1 year total shareholder return. This suggests momentum has cooled after a strong run as investors...

In recent weeks, Guardant Health and Helio Genomics each announced agreements with Quest Diagnostics to distribute their blood-based colorectal and liver cancer screening tests through Quest’s nationwide network, while the Quest board also appointed experienced healthcare executive Timothy Wentworth as a new director. Together, these moves deepen Quest’s role as an access point for innovative cancer detection while adding boardroom expertise in scaling complex healthcare platforms and...

Aveanna Healthcare Holdings (NasdaqGS:AVAH) announced the acquisition of Family First Homecare. The deal is intended to strengthen Aveanna's position in Florida and widen its geographic reach. The company also outlined a transformation that increased preferred payer agreements and set new M&A priorities for 2026. Aveanna Healthcare focuses on home based care services, an area many investors watch as care delivery shifts closer to the home. By adding Family First Homecare, the company is...

Investors may be wondering if EchoStar at around US$109.84 is still offering value after its substantial rise, or if most of the easier gains are already behind it. The stock has delivered a 315.1% return over the last year, even with a 4.4% decline over the past month and a 2.1% decline year to date. This can change how the market views its risk and reward trade off. Recent coverage has focused on EchoStar's sharp multi year share price gains and what that means for current holders and new...

In recent months, Robert Half reported quarterly revenue of US$1.30 billion, a 5.8% decline year on year, yet still ahead of analyst expectations, while earnings per share also surpassed forecasts. This mixed picture, set against years of sluggish long‑term growth and falling earnings per share, has intensified investor focus on how effectively the company can adapt its talent and consulting model as AI and digital pressures build. We’ll now examine how the revenue decline alongside an...

Geopolitical tensions in the Middle East, along with the related jump in energy prices, have put industrial stocks in focus again, with Curtiss-Wright (CW) drawing attention as investors reassess cost pressures and economic sensitivities. See our latest analysis for Curtiss-Wright. Curtiss-Wright’s share price has been volatile around geopolitical headlines, with a 1-day share price return of a 2.95% decline, a 90-day share price return of 20.96%, and a 1-year total shareholder return of...

If you are wondering whether Enerpac Tool Group at around US$35.97 is a bargain, fairly priced, or looking stretched, this article walks through the key valuation angles to help you frame that question clearly. The stock is roughly flat over the last week with a 0.3% return. That sits against a 14.7% decline over the last month and a 14.8% decline over the last year, even as the 3 year and 5 year returns are 37.7% and 38.0% respectively. Recent coverage has focused on how Enerpac Tool Group...

Raymond James announced that long-time executive Kirk Bell was appointed president of its Independent Contractor Division on April 1, 2026, joining the firm’s Senior Leadership and Private Client Group Executive teams after Shannon Reid’s departure. This leadership change matters because the Independent Contractor Division underpins Raymond James’ extensive advisor network, which oversees about US$1.67 billion in client assets across independent and employee channels. We’ll now examine how...

Earlier this month, Meta Platforms signed a 10-year lease with Vornado to turn its Manhattan Meta Lab at 697 Fifth Avenue into a five-level, 15,000-square-foot flagship store showcasing AI glasses and virtual reality headsets, expanding its physical retail presence beyond Los Angeles and Burlingame. This long-term Fifth Avenue commitment underscores how Meta is pairing heavy AI infrastructure spending with consumer-facing hardware and experiential retail to anchor its next phase of product...

ImmunityBio (NasdaqGS:IBRX) received its first Asian regulatory approval for ANKTIVA in Macau, marking the product’s initial foothold in the region. The company reported positive safety and feasibility data for its autologous memory cytokine enhanced NK (M ceNK) cell therapy platform, following completion of key manufacturing engineering and clinical translation work. For investors tracking ImmunityBio, these updates come as the stock trades at $8.47, with very large year to date returns...

Why Upstart’s new funding deal and bank plan matter for shareholders Upstart Holdings (UPST) has caught investor attention after securing a forward flow commitment to purchase up to US$1b of consumer loans and outlining plans to apply for a national bank charter. See our latest analysis for Upstart Holdings. Despite the funding deal and bank charter plan, the stock’s momentum has been weak, with a 30 day share price return of 17.6% and a 1 year total shareholder return decline of 50%, even...

Why United Natural Foods Stock Is on Investors’ Radar United Natural Foods (UNFI) has caught investor attention after a year where the stock’s total return sits at 48%, compared with a year-to-date move of 16% and a past 3 months return of 15.4%. Those returns sit against a mixed backdrop, with annual revenue of US$31.5b and a reported net income loss of US$78 million. This raises questions about how the current share price around US$38.77 reflects both its recent performance and its longer...

Wondering if First Mid Bancshares at around US$39.44 is giving you fair value or a potential bargain? This article breaks down what the current price might be implying about the business. The stock is roughly flat over the last week at 0.1%, has seen a 9.2% decline over the past month, yet is still up 2.1% year to date and 15.5% over the last year, with a 59.7% return across three years and 0.4% over five years. Recent coverage around regional banks has focused on how share prices react to...

Tesla stock performance in context Tesla (TSLA) has drawn fresh attention after a period of weaker share performance, with the stock showing a 3.2% decline over the past day, 5.9% over the past week, and a 10.5% pullback over the past month. See our latest analysis for Tesla. The recent pullback in Tesla’s share price, including a 23.5% 90 day share price return and a 16.0% year to date share price return, contrasts with a 47.95% 1 year total shareholder return and a 93.25% 3 year total...

Before putting fresh money into Snowflake, it helps to ask a simple question: does the current share price give you enough value for the growth story you have in mind? Over the last week the stock has seen a 6.0% decline, with a 4.6% decline over the past month and a 22.5% decline year to date, while the 1 year return sits at 6.1% and the 3 year return at 23.1%, compared to a 28.5% decline over 5 years from the starting point provided. Recent coverage has focused on Snowflake's position in...

Sun Communities: recent performance snapshot Sun Communities (SUI) has drawn fresh attention after recent share price moves, with the stock closing at $130.44 and showing mixed returns over the past week, month, past 3 months, year, and year to date. See our latest analysis for Sun Communities. The recent 1 day share price decline of 0.52% and 7 day share price return of negative 2.98% come after a year to date share price return of 6.80% and a 1 year total shareholder return of 6.23%. This...

Viavi Solutions (VIAV) has drawn fresh attention after unveiling its Observer Threat Forensics platform, a security and network visibility tool that will be showcased at the upcoming RSA Conference in San Francisco. See our latest analysis for Viavi Solutions. Those product launches around network security, AI driven infrastructure and fiber sensing have arrived alongside strong momentum, with a 30 day share price return of 19.41% and a 1 year total shareholder return of 170.57%, even after a...